ledipasvir and sofosbuvir

FDA Drug Profile — Harvoni

ledipasvir and sofosbuvir is listed in the FDA National Drug Code directory with 6 NDC codes, marketed under brand name including Harvoni. Available dosage forms: pellet, tablet, film coated.

Drug details

Generic Name
ledipasvir and sofosbuvir
Brand Names
Harvoni
Application Number
NDA212477
Sponsor
Gilead Sciences, Inc
NDC Codes
6
Dosage Forms
PELLET, TABLET, FILM COATED
Routes
ORAL
Active Ingredients
LEDIPASVIR, SOFOSBUVIR

Indications and Usage

1 INDICATIONS AND USAGE Ledipasvir and sofosbuvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14) ]: genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin Ledipasvir and sofosbuvir is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older: Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.